The European Society of Medical Oncology (ESMO) annual congress convened earlier this month in Paris, where, Illumina presented key abstracts demonstrating the clinical utility of comprehensive genomic profiling (CGP). CGP is a next-generation sequencing (NGS) approach that uses a single test to assess hundreds of genes—including relevant cancer biomarkers, as established in medical guidelines and clinical trials—for tumor therapy guidance.
Illumina, Inc. today announced that it has invested in six genomics startups for the fifth global funding cycle of Illumina Accelerator in the San Francisco Bay Area and Cambridge, UK.
Illumina, a global leader in DNA sequencing and array-based technologies, announced the release of the full agenda for its inaugural Illumina Genomics Forum.
At the 34th European Congress of Pathology (ECP) in Basel, Switzerland, September 3 to 7, 2022, pathologists from more than 100 countries will convene to share and gain insights on advancements in their field.
Illumina, a global leader in DNA sequencing and array-based technologies, announced that it will feature Dr. Karen Knudsen, CEO of the American Cancer Society, at its inaugural Illumina Genomics Forum (IGF) on October 1.
Illumina, a global leader in DNA sequencing and array-based technologies, announced today the release of Illumina DRAGEN™ v4.0, its most accurate and comprehensive secondary analysis platform.